Spyre Therapeutics: Validated Targets, Optimized Delivery
Source: SeekingAlpha
2026-01-01 04:36:34 ET
...
Read the full article on Seeking Alpha
For further details see:
Spyre Therapeutics: Validated Targets, Optimized Delivery
Spyre Therapeutics Inc.
NASDAQ: SYRE
SYRE Trading
6.7% G/L:
$43.46 Last:
590,521 Volume:
$40.73 Open:
SYRE Latest News
March 16, 2026 08:00:00 am
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
SYRE Stock Data
$2,603,991,883
65,619,664
1.61%
44
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
